doi: 10.5732/cjc.011.10205

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer

Joshua F. Heiber, Xiang-Xi Xu, Glen N. Barber

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. gbarber@med.miami.edu,xxu2@med.miami.edu.

[Abstract] In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer.

Chinese Journal of Cancer 2011, Volume: 30, Issue 12, Page: 805-814

[ PDF Full-text ]
[ PubMed ]
[Google Scholar]

Cite this article

Joshua F. Heiber, Xiang-Xi Xu, Glen N. Barber. Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer. Chin J Cancer. 2011, 30(12):805-814. doi:10.5732/cjc.011.10205


Export citations

EndNote